Ke-Qin Hu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8797617/publications.pdf

Version: 2024-02-01

331259 253896 1,900 61 21 43 citations h-index g-index papers 61 61 61 2206 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Infectious Diseases, 2022, 225, 1091-1099. | 1.9 | 17 |
| 2 | Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination. Hepatology, 2022, 75, 1664-1666. | 3.6 | O |
| 3 | Endoscopic Ultrasound-Guided Porto-systemic Pressure Gradient Measurement Correlates with Histological Hepatic Fibrosis. Digestive Diseases and Sciences, 2022, 67, 5685-5692. | 1.1 | 14 |
| 4 | Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data. Digestive Diseases and Sciences, 2021, 66, 1327-1334. | 1.1 | 3 |
| 5 | Ultrasonographic (US) Two-Dimensional Measurement of Spleen Is Superior to Traditional Length Measurement Alone in Diagnosing Cirrhosis. Digestive Diseases and Sciences, 2021, 66, 1335-1342. | 1.1 | 1 |
| 6 | New Year's greeting and overview of World Journal of Hepatology in 2021. World Journal of Hepatology, 2021, 13, 1-5. | 0.8 | 1 |
| 7 | The Treatment of Bacterial and Parasitic Diseases of the Liver. , 2020, , 211-225. | | 1 |
| 8 | Liver Cancer–Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2020, 11, e00271. | 1.3 | 7 |
| 9 | Direct acting antiviral-induced dynamic reduction of serum \hat{l}_{\pm} fetoprotein in hepatitis C patients without hepatocellular carcinoma. Frontiers of Medicine, 2019, 13, 658-666. | 1.5 | 1 |
| 10 | Hepadnaviruses: Virological and Clinical Features. , 2019, , . | | 1 |
| 11 | Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2019, 53, 147-154. | 1.1 | 4 |
| 12 | A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. Clinical and Translational Gastroenterology, 2019, 10, e00033. | 1.3 | 5 |
| 13 | Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. World Journal of Hepatology, 2019, 11, 442-449. | 0.8 | 5 |
| 14 | An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology and Therapeutics, 2018, 47, 1181-1200. | 1.9 | 40 |
| 15 | Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection. Digestive Diseases and Sciences, 2018, 63, 1237-1242. | 1.1 | 0 |
| 16 | EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study. VideoGIE, 2018, 3, 361-363. | 0.3 | 20 |
| 17 | Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. Journal of Clinical and Translational Hepatology, 2018, 6, 1-6. | 0.7 | 17 |
| 18 | Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection. Current Hepatology Reports, 2017, 16, 90-96. | 0.4 | 1 |

| # | Article | lF | CITATIONS |
|----|--|-----|-----------|
| 19 | EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study. Gastrointestinal Endoscopy, 2017, 85, 996-1001. | 0.5 | 124 |
| 20 | A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for Oneâ€step diagnosis of viremic hepatitis C virus infection. Hepatology, 2016, 64, 415-424. | 3.6 | 19 |
| 21 | Reply. Hepatology, 2016, 63, 2061-2062. | 3.6 | 0 |
| 22 | Overview on acute-on-chronic liver failure. Frontiers of Medicine, 2016, 10, 1-17. | 1.5 | 18 |
| 23 | Rethinking the pathogenesis of hepatitis B virus (HBV) infection. Journal of Medical Virology, 2015, 87, 1989-1999. | 2.5 | 36 |
| 24 | Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. PLoS ONE, 2015, 10, e0123065. | 1.1 | 63 |
| 25 | Clinical course of chronic hepatitis B (<scp>CHB</scp>) presented with normal <scp>ALT</scp> in Asian American patients. Journal of Viral Hepatitis, 2015, 22, 809-816. | 1.0 | 9 |
| 26 | A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prevention Research, 2015, 8, 864-872. | 0.7 | 13 |
| 27 | Prevalence and Presentation of Hepatitis B and C Virus (HBV and HCV) Infection in Vietnamese Americans via Serial Community Serologic Testing. Journal of Immigrant and Minority Health, 2015, 17, 13-20. | 0.8 | 19 |
| 28 | Impact of Occult Hepatitis B Virus Infection or Hepatitis B Virus DNA Integration on Efficacy of Chronic Hepatitis C Treatment With Peginterferon and Ribavirin. Journal of Clinical Gastroenterology, 2014, 48, 3-5. | 1.1 | 4 |
| 29 | Advances in Clinical Application of Cryoablation Therapy for Hepatocellular Carcinoma and Metastatic Liver Tumor. Journal of Clinical Gastroenterology, 2014, 48, 830-836. | 1.1 | 33 |
| 30 | Clinical Presentation and Disease Phases of Chronic Hepatitis B Using Conventional Versus Modified ALT Criteria in Asian Americans. Digestive Diseases and Sciences, 2014, 59, 865-871. | 1.1 | 13 |
| 31 | Advances in some common chronic liver diseases. Frontiers of Medicine, 2014, 8, 127-128. | 1.5 | 0 |
| 32 | Current hepatitis B treatment guidelines and future research directions. Frontiers of Medicine, 2014, 8, 145-157. | 1.5 | 5 |
| 33 | Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. North American Journal of Medicine & Science, 2014, 7, 21-27. | 3.8 | 5 |
| 34 | Long-Term Therapy with Nucleoside/Nucleotide Analogues for Chronic Hepatitis B in Asian Patients. Antiviral Therapy, 2013, 18, 841-852. | 0.6 | 14 |
| 35 | High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2012, 10, 1047-1050.e1. | 2.4 | 14 |
| 36 | Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. Journal of Viral Hepatitis, 2012, 19, 213-219. | 1.0 | 39 |

| # | Article | IF | Citations |
|----|--|-----|-----------|
| 37 | Preface. Clinics in Liver Disease, 2011, 15, xiii-xiv. | 1.0 | О |
| 38 | Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2011, 45, 720-726. | 1.1 | 18 |
| 39 | Barriers to Screening for Hepatitis B Virus Infection in Asian Americans. Digestive Diseases and Sciences, 2011, 56, 3163-3171. | 1.1 | 73 |
| 40 | Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans. Journal of Immigrant and Minority Health, 2011, 13, 842-848. | 0.8 | 26 |
| 41 | The Clinical Presentation of Chronic Hepatitis B Virus Infection in Asian Americans. Journal of Clinical Gastroenterology, 2010, 44, 364-370. | 1.1 | 12 |
| 42 | Histologic Evidence of Active Liver Injury in Chronic Hepatitis B Patients With Normal Range or Minimally Elevated Alanine Aminotransferase Levels. Journal of Clinical Gastroenterology, 2010, 44, 510-516. | 1.1 | 16 |
| 43 | W1804 Clinical Features of Chronic Hepatitis B (CHB) in Treatment NaÃ-ve Asian Patients with Positive HBeAg and Co-Existing Precore and/or Basal Core Promoter (PC/BCP) Mutations. Gastroenterology, 2009, 136, A-865. | 0.6 | 2 |
| 44 | Factors Associated With Hepatic Fibrosis In Patients With Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2009, 43, 758-764. | 1.1 | 41 |
| 45 | Hepatitis B Virus (HBV) Infection in Asian and Pacific Islander Americans (APIAs): How Can We Do Better for This Special Population. American Journal of Gastroenterology, 2008, 103, 1824-1833. | 0.2 | 63 |
| 46 | Clinical Implications of Hepatic Steatosis in Patients with Chronic Hepatitis C: A Multicenter Study of U.S. Veterans. Digestive Diseases and Sciences, 2007, 52, 570-578. | 1.1 | 27 |
| 47 | Hepatitis C in patients with chronic kidney disease: Course and management. Current Hepatitis Reports, 2007, 6, 96-102. | 0.3 | 1 |
| 48 | Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. Journal of Viral Hepatitis, 2006, 13, 242-249. | 1.0 | 39 |
| 49 | Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection. American Journal of Gastroenterology, 2005, 100, 1772-1779. | 0.2 | 168 |
| 50 | Clinical Presentation of Chronic Hepatitis C in Patients with End-Stage Renal Disease and on Hemodialysis Versus Those with Normal Renal Function. American Journal of Gastroenterology, 2005, 100, 2010-2018. | 0.2 | 33 |
| 51 | In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells. Clinical Cancer Research, 2005, 11, 8213-8221. | 3.2 | 73 |
| 52 | A Practical Approach to Management of Chronic Hepatitis B. International Journal of Medical Sciences, 2005, 2, 17-23. | 1.1 | 8 |
| 53 | Clinical Significance of Elevated Alpha-Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but not Hepatocellular Carcinoma. American Journal of Gastroenterology, 2004, 99, 860-865. | 0.2 | 156 |
| 54 | Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. Journal of Hepatology, 2004, 40, 147-154. | 1.8 | 118 |

KE-QIN Hu

| # | Article | IF | CITATION |
|----|---|-----|----------|
| 55 | Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. International Journal of Medical Sciences, 2004, 1, 92-100. | 1.1 | 10 |
| 56 | Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 69, 329-337. | 1.0 | 47 |
| 57 | Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. International Journal of Oncology, 2003, 22, 757-63. | 1.4 | 15 |
| 58 | Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. Translational Research, 2002, 139, 234-243. | 2.4 | 60 |
| 59 | Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis, 2001, 8, 1-18. | 1.0 | 71 |
| 60 | The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the united states. Hepatology, 1999, 29, 1311-1316. | 3.6 | 249 |
| 61 | Simultaneous detection of both hepatitis B virus DNA and hepatitis C virus RNA using a combined one-step polymerase chain reaction technique. Hepatology, 1995, 21, 901-907. | 3.6 | 8 |